EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

Paul G Richardson, Suzanne Trudel, Rakesh Popat, María-Victoria Mateos, Annette J Vangsted, Karthik Ramasamy, Joaquín Martinez-Lopez, Hang Quach, Robert Z Orlowski, Mario Arnao, Sagar Lonial, Chatchada Karanes und 20 weitere

New England Journal of Medicine · 14.09.2023 · 389 (11) · 1009-1022

DOI: 10.1056/nejmoa2303194 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 14.09.2023. Verfasst von Paul G Richardson und 31 weiteren Autor:innen. Beteiligte Einrichtung: From Dana-Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of T…. Hauptthemen laut MEDLINE: Dexamethasone, Multiple Myeloma, Antineoplastic Agents, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Cancer Research UK, Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneMultiple MyelomaAntineoplastic AgentsUbiquitin-Protein LigasesHumansAntibodiesLenalidomideNeutropeniaAdministration, OralRecurrenceAdaptor Proteins, Signal Transducing

Substanzen

AntibodiesDexamethasoneLenalidomideAntineoplastic AgentsUbiquitin-Protein LigasesCRBN protein, humanAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • From Dana-Farber Cancer Institute, Boston (P.G.R.); the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto (S.T.), and Arnie Charbonneau Cancer Institute, Univer…

Förderung

  • Cancer Research UK
  • Bristol-Myers Squibb

Zitieren

APA

Richardson, P. G., Trudel, S., Popat, R., Mateos, M. V., Vangsted, A. J., Ramasamy, K., Martinez-Lopez, J., Quach, H., Orlowski, R. Z., Arnao, M., Lonial, S., Karanes, C., Pawlyn, C., Kim, K., Oriol, A., Berdeja, J. G., Rodríguez Otero, P., Casas-Avilés, I., Spirli, A., …, & CC-92480-MM-001 Study Investigators (2023). Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 389(11), 1009-1022. https://doi.org/10.1056/nejmoa2303194

Vancouver

Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, et al. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine. 2023;389(11):1009-1022. doi:10.1056/nejmoa2303194

BibTeX
@article{Richardson2023,
  author = {Richardson, Paul G and Trudel, Suzanne and Popat, Rakesh and Mateos, María-Victoria and Vangsted, Annette J and Ramasamy, Karthik and Martinez-Lopez, Joaquín and Quach, Hang and Orlowski, Robert Z and Arnao, Mario and Lonial, Sagar and Karanes, Chatchada and Pawlyn, Charlotte and Kim, Kihyun and Oriol, Albert and Berdeja, Jesus G and Rodríguez Otero, Paula and Casas-Avilés, Ignacio and Spirli, Alessia and Poon, Jennifer and Li, Shaoyi and Gong, Jing and Wong, Lilly and Lamba, Manisha and Pierce, Daniel W and Amatangelo, Michael and Peluso, Teresa and Maciag, Paulo and Katz, Jessica and Pourdehnad, Michael and Bahlis, Nizar J and CC-92480-MM-001 Study Investigators, CC-92480-MM-001 Study Investigators},
  title = {Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {11},
  pages = {1009--1022},
  doi = {10.1056/nejmoa2303194}
}
Kostenlos starten →